Sublingual Atropine Administration as a Tool to Decrease Salivary Glands’ PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [68Ga]Ga-PSMA-11
Nail, V.; Louis, B.; Moyon, A.; Chabert, A.; Balasse, L.; Fernandez, S.; Hache, G.; Garrigue, P.; Taïeb, D.; Guillet, B. Sublingual Atropine Administration as a Tool to Decrease Salivary Glands’ PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [68Ga]Ga-PSMA-11. Pharmaceutics 2022, 14, 1276. https://doi.org/10.3390/pharmaceutics14061276
Nail V, Louis B, Moyon A, Chabert A, Balasse L, Fernandez S, Hache G, Garrigue P, Taïeb D, Guillet B. Sublingual Atropine Administration as a Tool to Decrease Salivary Glands’ PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [68Ga]Ga-PSMA-11. Pharmaceutics. 2022; 14(6):1276. https://doi.org/10.3390/pharmaceutics14061276
Chicago/Turabian StyleNail, Vincent, Béatrice Louis, Anaïs Moyon, Adrien Chabert, Laure Balasse, Samantha Fernandez, Guillaume Hache, Philippe Garrigue, David Taïeb, and Benjamin Guillet. 2022. "Sublingual Atropine Administration as a Tool to Decrease Salivary Glands’ PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [68Ga]Ga-PSMA-11" Pharmaceutics 14, no. 6: 1276. https://doi.org/10.3390/pharmaceutics14061276